NCT02111707View on ClinicalTrials.gov

Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

PHASE4CompletedINTERVENTIONAL

Enrollment

534

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Acute Pancreatitis

Interventions

DRUG

Rectal indomethacin 100mg one time before or after ERCP

Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.

Trial Locations (1)

T6G2X8

University of Alberta, Edmonton

All Listed Sponsors

lead

University of Alberta

OTHER

NCT02111707 - Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) | Biotech Hunter | Biotech Hunter